SUMMARY One hundred and twenty nine de novo patients with idiopathic Parkinson's disease are being followed over a 5 year period in a double-blind multicentre study comparing low-dose bromocriptine (< 30 mg/day) with low-dose levodopa-carbidopa (< 600/150 mg/day). Sixty six patients have been randomised to bromocriptine and 63 patients to levodopa-carbidopa. Improvement has been greater in the levodopa-carbidopa group than in the bromocriptine group. Involuntary movements have so far only occurred in patients on levodopa-carbidopa, the incidence being much lower than is usually described with conventional doses. Mild, end-of-dose failure has occurred in both treatment groups; however, no patient has developed the "on-off' phenomenon. Low-dose levodopa-carbidopa appears to be a more effective anti-Parkinsonian treatment than lowdose bromocriptine but more prone to cause dyskinesia.
The value of levodopa in the long-term treatment of Parkinson's disease is limited by the emergence of dyskinesia and the "on-of' phenomenon.'-3 Attempts to reduce the incidence of these problems by giving levodopa in low dosage have met with limited success.45 Dyskinesia has rarely been observed and the "on-off" phenomenon has not been described in patients treated with bromocriptine alone.'5 Nausea, postural hypotension and confusion limit the use of bromocriptine in up to 35% of patients using conventional doses.>" Several studies have shown that these side-effects can be minimised by giving bromocriptine in low dosage. '1213 The aim of this study is to compare the efficacy and side-effects of low dose bromocriptine (< 30 mg/day) with low-dose levodopa-carbidopa (< 600/150 mg/ day) over a 5 year period in de novo patients. We report the results ofthe first 3 years of the study during which patients were recruited.
Methods
One hundred and forty nine patients with idiopathic Parkinson's disease were recruited over a 3 year period from neurologists and general practitioners in the Sydney area.
neurologists and general practitioners in the Sydney area.
Although the target population was de novo patients, 15 patients who had received levodopa for less than 3 months were accepted into the study. This medication was ceased one month prior to the patient entering the trial. Four Sydney hospitals are participating in the study. At each hospital clinic a participating neurologist confirmed the diagnosis of idiopathic Parkinson's disease and the need to commence treatment. Patients were then stratified according to age and previous treatment (18 patients had been taking anticholinergics, 11 patients levodopa-carbidopa alone and 4 patients anticholinergics and levodopa-carbidopa). They were then randomised to receive either bromocriptine or levodopacarbidopa. Informed consent was obtained.
Patients were given a placebo preparation for 1 month during which time two baseline assessments were made. They were then given either 1 mg/day ofbromocriptine or 20/5 mg/ day oflevodopa-carbidopa in identical looking capsules. The dose was increased gradually at weekly, then monthly intervals until the patient reported a satisfactory response. If the patient was receiving anticholinergics or amantadine, these were continued unchanged during the trial. Only the hospital pharmacist knew which drug the patient was taking. The code was broken only if: (1) the response was unsatisfactory, (2) unacceptable side-effects occurred, (3) a greater than maximum trial dose was required, (4) one of the trial endpoints occurred. The main end-points listed in the trial protocol were dyskinesia and the "on-of' phenomenon. If the response was inadequate, wherever possible the original trial drug was continued and the dose increased above the "low-dose" maximum of 30 mg/day of bromocriptine and 600/150 mg/day of levodopa-carbidopa. Patients continue to 324 be followed even if they are no longer on the therapy initially allocated.
The patients were seen monthly for about 6 months during which time the hospital neurologists titrated the dose (Phase I). Thereafter, the patients returned to their referring neurologists for the major part of their care but continue to be assessed in the hospital clinics at six monthly intervals for four and a half years (Phase II).
One neurologist attends all clinics in addition to the four hospital neurologists and examines all patients at baseline, end of titration phase and yearly thereafter. At regular intervals a comparison is made between the scores of this neurologist and the hospital neurologists, following simultaneous independent examinations of patients, with the aim of achieving uniformity between the four participating hospitals.
Signs The results of patients in the double blind aspect of the study have been analysed by the study statistician, the participating neurologists remaining blind to the drug being administered to individual patients.
Results

Exclusions
Of the 149 patients referred into the study, 10 have been excluded because they had the following: cystic lesion of the basal ganglia on CT (1), essential tremor (2), undetermined congenital disorder (2), progressive supranuclear palsy (1), Shy-Drager syndrome (1), suspected striato-nigral degeneration (1), pinealoma and hydrocephalus (1), life-long non-progressive bradykinesia (1). Ten further patients failed to complete Phase I: four moved elsewhere, five were noncompliant and one died from myocardial infarction. whom confusion occurred with bromocriptine, five had evidence of dementia at baseline. Involuntary movements were the main reason for breaking the treatment code in patients receiving levodopa-carbidopa. Dyskinesia (choreo-athetoid movements often occurring at peak-dose times) began at a mean of 16 months (range 7-24 months) after commencing medication. The mean duration of disease prior to the onset of dyskinesia was 44 months (range 14-60 months). Nineteen percent of patients (six out of 32) had developed dyskinesia after 2 years on levodopa-carbidopa. Foot dystonia (sustained inversion of the foot, clawing of the toes or dorsiflexion of the large toe) appeared at a mean of 21 months (range 12-30 months) after treatment and after a mean duration of disease of 44 months (range 25-78 months). Sixteen percent of patients (five out of 32) had developed foot dystonia after 2 years.
Patient cohorts
Six patients on levodopa-carbidopa, three on bromocriptine and one on combined therapy have reported mild, end-of-dose deterioration. All three patients on bromocriptine had moderately severe disease, with Columbia scores of about 30. In no case was the end-of-dose deterioration sufficiently severe to require an increased frequency of dosage of bromocriptine. Four of the six patients with this problem in the levodopa-carbidopa group are now taking the drug four or more times daily.
Changes in the Columbia scores Changes in the Columbia scores at 1 and 2 years of all patients remaining on their initial therapy, regardless of whether the treatment code had been broken, are shown in tables 5 and 6. More patients improved and these to a greater degree on levodopa-carbidopa than on bromocriptine. At 1 year, 59% of patients on levodopa-carbidopa and 31% of patients on bromocriptine had a 20% reduction in the Columbia score. At 2 years, 58% of patients on levodopacarbidopa and 7% of patients on bromocriptine had improved by 20% or more. Patients who improved on low-dose bromocriptine tended to have mild disease with tremor. The number of patients who have been in the trial for 3 years is not sufficient for a meaningful analysis.
Follow-up ofpatients no longer on initial therapy alone Twenty two patients did not improve on bromocriptine and had sufficient disability to warrant breaking the treatment code. Of these, 12 out of 13 improved when levodopa-carbidopa was added to the bromocriptine and six out of seven improved when bromocriptine was replaced by levodopa-carbidopa. Six out of 10 patients who became confused on bromocriptine also developed confusion on levodopacarbidopa.
Three patients, in whom levodopa has replaced bromocriptine, have developed dyskinesia after a mean of 15 months (range 4-31 months) on levodopa, while two other patients have developed dystonia of the foot after 2 and 12 months respectively on levodopa. The mean period of treatment with bromocriptine for these five patients was 16 months (range 5-33 months) prior to its cessation. All four patients who had an inadequate response to low-dose levodopa responded to higher doses (mean 900 mg/day).
Discussion
Differences in methods of assessment, duration of disease and previous treatment make it difficult to compare the results of this low-dose study with those of studies using conventional doses of levodopa. Comparisons with conventional doses of bromocriptine are rendered even more difficult by the fact that bromocriptine is used as an adjunct to levodopa in most studies. Nevertheless, there can be little doubt that fewer of our patients, both in the levodopacarbidopa and bromocriptine groups, have improved, and these to a lesser degree than patients treated with high doses oflevodopa. After 2 years oftreatment with conventional doses of levodopa, 63-77% of patients showed more than 20-25% improvement in three large studies.""'9 By comparison, 58% of patients originally allocated levodopa-carbidopa and only 7% of patients originally allocated bromocriptine had *peak dose dyskinesias only tAIMS not specified improved more than 20% at 2 years in this study. Moreover, the proportion of patients who had improved at 2 years was lower than at I year in the bromocriptine treatment group, suggesting a waning of therapeutic effect with time.
Lest it appear that we are condemning our patients to unnecessary hardship, it should be recalled that the aim of this study was to try to avoid the long-term problems associated with levodopa and bromocriptine therapy by giving the lowest dose which produced a satisfactory response. Our guiding principle was, therefore, to increase the dose of each drug until the patient reported a satisfactory response. This might involve an increase in independence or a return to previously abandoned activities and not be reflected in the Columbia score. Being a de novo study, many of our patients have mild disease (Hoehn and Yahr stage I and II), and a failure to show objective improvement in clinical signs at this stage is of little importance. Patients remaining in the double blind aspect of the study are all satisfied with their progress to date. This is the case after 2 years in 26 out of 32 patients in the levodopa-carbidopa group and in 14 out of 27 patients in the bromocriptine group.
Most published studies include patients with moderate or severe disability. In such patients the main aim of treatment is to produce maximal improvement. A similar approach was followed in 26 patients in this study who did not improve on the lowdose regimen and who had moderately severe or rapidly progressive disease (Hoehn and Yahr stage III and IV). In these patients the low-dose therapy was abandoned and conventional doses of levodopa-carbidopa and bromocriptine were given either singly or in combination.
This study confirms the findings of Poewe, Lees and Sternm that giving levodopa at low dosage does not prevent some patients from getting involuntary movements. The incidence, however, is considerably lower than with conventional doses (see 
